Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.53 |
| ▸ | LPL | P06858 | 8/20 | 0.53 |
| ▸ | PGR | P06401 | 8/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628353 | 0.96 | LIPG (0.57) | LIPGLPLPGRESR2CYP19A1 | |
| SCHEMBL23020133 | 0.92 | LIPG (0.44) | LIPGLPLPGRGABRA1GABRG2 | |
| SCHEMBL31625405 | 0.89 | LIPG (0.59) | LIPGLPLGABRA1GABRG2GABRB3 | |
| SCHEMBL24443047 | 0.88 | LIPG (0.43) | LIPGLPLPGRGABRA1GABRG2 | |
| SCHEMBL20088886 | 0.87 | LIPG (0.68) | LIPGLPL | |
| SCHEMBL20088879 | 0.87 | LIPG (0.68) | LIPGLPL | |
| SCHEMBL20088874 | 0.87 | LIPG (0.68) | LIPGLPL | |
| SCHEMBL17702117 | 0.87 | LIPG (0.68) | LIPGLPL | |
| SCHEMBL18134363 | 0.87 | LIPG (0.68) | LIPGLPL | |
| SCHEMBL30025201 | 0.87 | LIPG (0.68) | LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019066340-A1 | ORGANIC COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | 삼성에스디아이 주식회사 | 2019-04-04 | — | — | WO | disclosed |
| US-20160122405-A1 | HOMEODOMAIN FUSION PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122405-A1 | HOMEODOMAIN FUSION PROTEINS AND USES THEREOF | ZFX, CNBP, CDYL | LIPG 3494/4885LPL 2962/4885PGR 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.